pH-Responsive LLC Lipid Carriers for Targeted Agent Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmaceutical and cosmetic agents face challenges such as poor solubility, low cellular permeability, chemical and biological instability, rapid degradation, and systemic delivery issues, leading to off-target effects and reduced efficacy.
Innovation Solution
Development of lyotropic liquid crystalline (LLC) lipid carriers comprising structural lipids and amino lipids with amido-linkers that undergo pH-responsive mesophase transitions, allowing controlled release of active agents at specific physiological conditions, such as in tumors or infected sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biologically active agents are administered systemically, then they can reach disease sites, but they also cause off-target effects and toxicity to normal cells
Solution Approach 1:
The lipid carrier is designed with pH-sensitive amino lipids that remain stable at neutral pH (circulating blood) but undergo structural changes at acidic pH (tumor microenvironment). This local responsiveness ensures the carrier maintains integrity during systemic circulation and only releases the active agent at the target site with acidic conditions, achieving selective local delivery while minimizing off-target effects
Solution Approach 2:
The invention exploits the parameter change of pH between normal physiological conditions (pH 7.4) and disease sites (pH 6.5-7.0). The amino lipids in the carrier are selected to be stable at pH 7.4 but undergo phase transition or structural reorganization at lower pH, triggering controlled release of the active agent specifically at the acidic tumor microenvironment while maintaining stability during systemic circulation at neutral pH
2Reliability
If biologically active agents are delivered to improve efficacy, then treatment effectiveness increases, but chemical and biological instability leads to rapid degradation
Solution Approach 1:
The active agent is encapsulated within the lipid carrier structure, nesting the fragile agent inside a protective lipid shell. This encapsulation protects the active agent from chemical and biological degradation in the circulation environment while allowing controlled release at the target site, thereby maintaining both stability during transport and efficacy at the destination
Solution Approach 2:
The lipid carrier acts as an intermediary between the active agent and the biological environment. It shields the agent from harmful enzymes and metabolic processes during circulation, then facilitates controlled release at the target site through pH-responsive structural changes, ensuring both stability during transport and efficacy at the destination
3Productivity
If conventional carriers are used to deliver active agents, then delivery is achieved, but poor solubility and low cellular permeability reduce effectiveness
Solution Approach 1:
The lipid carrier is formulated as a composite system containing structural lipids for stability, pH-sensitive amino lipids for responsive release, and hydrophilic/hydrophobic components for solubility enhancement. This composite structure improves the solubility of poorly water-soluble active agents while maintaining cellular permeability through the amphiphilic nature of the lipid components, thereby enhancing both delivery efficiency and effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances targeted delivery and controlled release of biologically active agents, improving efficacy and reducing off-target side effects by exploiting structural changes in lipid carriers under physiological pH conditions.
Implementation Method 1
the LLC lipid carrier adapted to undergo a mesophase transition upon exposure to a drop in pH
Implementation Method 2
By exploiting the structural phase changes in the lipid carriers under appropriate physiological conditions (e.g., decreased pH), the release of encapsulated active agents from the lipid carriers can be controlled
Data Source
AI summary
The present disclosure relates to a lyotropic liquid crystalline lipid carrier which is useful for the delivery of active agents. The present disclosure also relates to cosmetic or pharmaceutical compositions comprising the lipid carrier, and methods of using the lipid carrier or compositions thereof to treat, prevent or diagnose diseases, disorders or conditions such as cancer or bacterial or fungal infections.